Veracyt announced that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company’s global product development strategy. Dr. Haas will join Veracyte (VCYT) on March 24, 2026, and he will be responsible for overseeing the company’s end-to-end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte price target lowered to $37 from $48 at Morgan Stanley
- Veracyte Inc. Signals Durable Growth in Earnings Call
- Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
- Veracyte reports Q4 EPS 51c, consensus 41c
- Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M